Cytokine	B:C0079189
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	B:C0751968
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	B:C0044602
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	B:C0243192
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	B:C0034783
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	B:C0003402
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	B:C0022116
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	B:C0007587
death	I:C0007587
in	O
rat	O
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	B:C0034693
hippocampal	O
cultures	O
.	O

Cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
activators	O
of	O
PI3	O
-	I:C0044602
kinase	I:C0044602
,	O
agonists	O
of	O
α	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	I:C0007587
in	O
rat	O
hippocampal	B:C0019564
cultures	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	B:C0079189
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	B:C0044602
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	B:C0751968
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	B:C1254351
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	B:C0243192
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	B:C0034783
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	B:C0079466
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	B:C0147760
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	B:C1254351
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	B:C3179302
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	B:C1873178
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	B:C1254351
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	B:C0019564
cell	O
culture	O
during	O
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL	O
-	I:C0085295
10	I:C0085295
with	O
the	O
action	O
of	O
a	O
PI3	O
-	I:C0044602
kinase	I:C0044602
selective	O
activator	I:C0751968
740	O
Y	I:C1254351
-	I:C1254351
P	I:C1254351
,	O
selective	O
agonists	I:C0243192
of	O
alpha	O
-	I:C0034783
2	I:C0034783
adrenoreceptor	I:C0034783
,	O
guanfacine	O
and	O
UK	O
-	I:C0147760
14,304	I:C0147760
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	I:C3179302
:	O
recombinant	O
human	O
peroxiredoxin	I:C1873178
6	I:C1873178
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	B:C4236780
OGD	I:C4236780
(	O
ischemia	O
-	O
like	O
conditions	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
response	B:C4236780
of	I:C4236780
cells	I:C4236780
to	I:C4236780
OGD	I:C4236780
in	O
the	O
control	O
includes	O
two	O
phases	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	B:C0600430
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
(	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
)	O
in	O
neurons	O
and	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
-	O
pulse	O
in	O
astrocytes	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
(	O
spontaneous	B:C0600430
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
)	O
in	O
neurons	O
and	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
-	O
pulse	O
in	O
astrocytes	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
(	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
)	O
in	O
neurons	B:C0027882
and	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
-	O
pulse	O
in	O
astrocytes	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
(	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
)	O
in	O
neurons	O
and	O
Ca(	B:C0596235
2	I:C0596235
+	I:C0596235
)	I:C0596235
-	O
pulse	O
in	O
astrocytes	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
(	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
)	O
in	O
neurons	O
and	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
-	O
pulse	B:C0391850
in	O
astrocytes	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
(	O
spontaneous	O
synchronous	I:C0600430
Ca(	I:C0600430
2	I:C0600430
+	I:C0600430
)	I:C0600430
-	I:C0600430
oscillations	I:C0600430
)	O
in	O
neurons	O
and	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
-	O
pulse	O
in	O
astrocytes	B:C0004112
.	O

Spontaneous	O
Ca(	B:C0596235
2+	I:C0596235
)	I:C0596235
events	O
in	O
astrocytes	O
during	O
ischemia	O
in	O
control	O
experiments	O
disappeared	O
.	O

Spontaneous	O
Ca(	O
2+	I:C0596235
)	I:C0596235
events	O
in	O
astrocytes	B:C0004112
during	O
ischemia	O
in	O
control	O
experiments	O
disappeared	O
.	O

Spontaneous	O
Ca(	O
2+	I:C0596235
)	I:C0596235
events	O
in	O
astrocytes	O
during	O
ischemia	B:C0022116
in	O
control	O
experiments	O
disappeared	O
.	O

Spontaneous	O
Ca(	O
2+	I:C0596235
)	I:C0596235
events	O
in	O
astrocytes	O
during	O
ischemia	O
in	O
control	O
experiments	O
disappeared	B:C0243095
.	O

The	O
second	O
phase	O
started	O
after	B:C4236780
a	I:C4236780
few	I:C4236780
minutes	I:C4236780
of	I:C4236780
OGD	I:C4236780
and	O
looked	O
like	O
a	O
sharp	O
/	I:C0243095
avalanche	I:C0243095
,	O
global	O
synchronic	I:C0243095
(	O
within	O
20	O
s	O
)	O
increase	O
in	O
[	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
in	O
many	O
cells	O
.	O

The	O
second	O
phase	O
started	O
after	O
a	I:C4236780
few	I:C4236780
minutes	I:C4236780
of	I:C4236780
OGD	I:C4236780
and	O
looked	O
like	O
a	O
sharp	B:C0243095
/	I:C0243095
avalanche	I:C0243095
,	O
global	O
synchronic	I:C0243095
(	O
within	O
20	O
s	O
)	O
increase	O
in	O
[	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
in	O
many	O
cells	O
.	O

The	O
second	O
phase	O
started	O
after	O
a	I:C4236780
few	I:C4236780
minutes	I:C4236780
of	I:C4236780
OGD	I:C4236780
and	O
looked	O
like	O
a	O
sharp	O
/	I:C0243095
avalanche	I:C0243095
,	O
global	B:C0243095
synchronic	I:C0243095
(	O
within	O
20	O
s	O
)	O
increase	O
in	O
[	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
in	O
many	O
cells	O
.	O

The	O
second	O
phase	O
started	O
after	O
a	I:C4236780
few	I:C4236780
minutes	I:C4236780
of	I:C4236780
OGD	I:C4236780
and	O
looked	O
like	O
a	O
sharp	O
/	I:C0243095
avalanche	I:C0243095
,	O
global	O
synchronic	I:C0243095
(	O
within	O
20	O
s	O
)	O
increase	O
in	O
[	O
Ca(	B:C0596235
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
in	O
many	O
cells	O
.	O

The	O
second	O
phase	O
started	O
after	O
a	I:C4236780
few	I:C4236780
minutes	I:C4236780
of	I:C4236780
OGD	I:C4236780
and	O
looked	O
like	O
a	O
sharp	O
/	I:C0243095
avalanche	I:C0243095
,	O
global	O
synchronic	I:C0243095
(	O
within	O
20	O
s	O
)	O
increase	O
in	O
[	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
in	O
many	O
cells	B:C0007634
.	O

Within	O
1	O
h	O
after	B:C4236780
OGD	I:C4236780
,	O
a	O
mass	O
death	I:C0007587
of	I:C0007587
cells	I:C0007587
,	O
primarily	O
astrocytes	O
,	O
was	O
observed	O
.	O

Within	O
1	O
h	O
after	O
OGD	I:C4236780
,	O
a	O
mass	B:C0007587
death	I:C0007587
of	I:C0007587
cells	I:C0007587
,	O
primarily	O
astrocytes	O
,	O
was	O
observed	O
.	O

Within	O
1	O
h	O
after	O
OGD	I:C4236780
,	O
a	O
mass	O
death	I:C0007587
of	I:C0007587
cells	I:C0007587
,	O
primarily	O
astrocytes	B:C0004112
,	O
was	O
observed	O
.	O

To	O
study	O
the	O
protective	O
action	O
of	O
the	O
compounds	B:C1254351
,	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
neuroprotective	O
agents	I:C0242912
for	O
10	O
-	O
40	O
min	O
or	O
24	O
h	O
before	O
ischemia	O
.	O

To	O
study	O
the	O
protective	O
action	O
of	O
the	O
compounds	O
,	O
cells	B:C0007634
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
neuroprotective	O
agents	I:C0242912
for	O
10	O
-	O
40	O
min	O
or	O
24	O
h	O
before	O
ischemia	O
.	O

To	O
study	O
the	O
protective	O
action	O
of	O
the	O
compounds	O
,	O
cells	O
were	O
incubated	B:C1439852
in	O
the	O
presence	O
of	O
the	O
neuroprotective	O
agents	I:C0242912
for	O
10	O
-	O
40	O
min	O
or	O
24	O
h	O
before	O
ischemia	O
.	O

To	O
study	O
the	O
protective	O
action	O
of	O
the	O
compounds	O
,	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
neuroprotective	B:C0242912
agents	I:C0242912
for	O
10	O
-	O
40	O
min	O
or	O
24	O
h	O
before	O
ischemia	O
.	O

To	O
study	O
the	O
protective	O
action	O
of	O
the	O
compounds	O
,	O
cells	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
neuroprotective	O
agents	I:C0242912
for	O
10	O
-	O
40	O
min	O
or	O
24	O
h	O
before	O
ischemia	B:C0022116
.	O

All	O
the	O
neuroprotective	B:C0242912
agents	I:C0242912
delayed	O
a	O
global	O
[	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
increase	O
during	O
OGD	I:C4236780
or	O
completely	O
inhibited	O
this	O
process	O
and	O
increased	O
cell	O
survival	I:C0007620
.	O

All	O
the	O
neuroprotective	O
agents	I:C0242912
delayed	O
a	O
global	O
[	O
Ca(	B:C0596235
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
increase	O
during	O
OGD	I:C4236780
or	O
completely	O
inhibited	O
this	O
process	O
and	O
increased	O
cell	O
survival	I:C0007620
.	O

All	O
the	O
neuroprotective	O
agents	I:C0242912
delayed	O
a	O
global	O
[	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
increase	O
during	B:C4236780
OGD	I:C4236780
or	O
completely	O
inhibited	O
this	O
process	O
and	O
increased	O
cell	O
survival	I:C0007620
.	O

All	O
the	O
neuroprotective	O
agents	I:C0242912
delayed	O
a	O
global	O
[	O
Ca(	O
2	I:C0596235
+	I:C0596235
)	I:C0596235
]	O
i	O
increase	O
during	O
OGD	I:C4236780
or	O
completely	O
inhibited	O
this	O
process	O
and	O
increased	O
cell	B:C0007620
survival	I:C0007620
.	O

